Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Title
Intervention Indication Therapeutic Area Year Actions
Tisagenlecleucel for relapsed or refractory follicular lymphoma Tisagenlecleucel-T (Kymriah; CTL019) Follicular lymphoma Haematological Cancer and Lymphomas 2021 View  |  Download
Tisagenlecleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma – second line Tisagenlecleucel-T (Kymriah; CTL019) B-cell non-Hodgkin lymphoma Haematological Cancer and Lymphomas 2021 View  |  Download
Tislelizumab for advanced non-small cell lung cancer after platinum based chemotherapy Tislelizumab (BGB-A317; BGBA-317) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Tislelizumab for oesophageal cancer – second line Tislelizumab (BGB-A317; BGBA-317) Oesophageal cancer Head and Neck Cancer 2021 View  |  Download
Tislelizumab for treating unresectable, previously untreated hepatocellular carcinoma Tislelizumab (BGB-A317; BGBA-317) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Tislelizumab in combination with chemotherapy for nasopharyngeal cancer – first line Cisplatin (Platinol) , Gemcitabine (Gemzar; gemcitabine hydrochloride) , Tislelizumab (BGB-A317; BGBA-317) Nasopharyngeal cancer Head and Neck Cancer 2021 View  |  Download
Tislelizumab in combination with Paclitaxel, Cisplatin, and Radiotherapy for Oesophageal cancer Cisplatin (Platinol) , Paclitaxel (Taxol; paclitaxel albumin) , Tislelizumab (BGB-A317; BGBA-317) Squamous cell carcinoma (SCC) Head and Neck Cancer 2022 View  |  Download
Tislelizumab with chemotherapy for previously untreated advanced squamous or non-squamous non-small-cell lung cancer Tislelizumab (BGB-A317; BGBA-317) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Tislelizumab with chemotherapy for previously untreated unresectable or metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma Chemotherapy , Tislelizumab (BGB-A317; BGBA-317) Gastric cancer , Gastro-oesophageal junction adenocarcinoma Gastrointestinal Cancer 2022 View  |  Download
Tislelizumab with chemotherapy for previously
untreated advanced oesophageal squamous cell
carcinoma
Tislelizumab (BGB-A317; BGBA-317) Oesophageal squamous cell carcinoma Gastrointestinal Cancer 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications